PHARMACEUTICAL COMPOUNDS Russian patent published in 2022 - IPC C07D401/14 C07D401/08 C07D403/04 C07D403/14 C07D417/14 C07D491/107 C07D498/08 A61K31/403 A61P25/28 

FIELD: pharmaceutics.

SUBSTANCE: invention relates to a compound which is a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein: X¹ and X² are saturated hydrocarbon groups, which together contain a total of five to nine carbon atoms and none or one oxygen atom and which are connected to each other in such a way that the functional group (a) forms a monocyclic or bicyclic ring system; R¹ is selected from OR⁵; NR⁵R⁶; COOR⁵; CONR⁵R⁶; CONR⁵OR⁶; C(=NOR⁵)R⁶; CH₂NR⁷COR⁵; C_1-3alkyl group, which is substituted with one to three fluorine atoms; and 5-member ring containing 2 heteroatoms selected from N and S, substituted with methyl; R⁴ is H or C_1-3 alkyl group; and R⁵, R⁶ and R⁷ are identical or different, and each of them is independently selected from hydrogen, a non-aromatic C_1-6saturated hydrocarbon group, optionally substituted with one or more fluorine atoms or optionally substituted with a phenyl ring; or R⁵ and R⁶ can be bonded to each other to form a monocyclic or bicyclic ring containing 1 or 2 heteroatoms selected from O and N, optionally substituted with methyl; or ethyl 4-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]piperidine-1-carboxylate or a pharmaceutically acceptable salt thereof. Invention also relates to a pharmaceutical composition for treating a disease or condition mediated by muscarinic receptors M₁ and/or M₄, containing a compound of the invention and a pharmaceutically acceptable excipient.

(1),

(а)

EFFECT: compounds having muscarinic receptor agonist activity M₁ and/or M₄, and intended for use in treating a cognitive disorder or psychotic disorder or for treating or reducing the severity of acute, chronic, neuropathic or inflammatory pain.

15 cl, 4 tbl, 52 ex